Effects of acebutolol and propranolol on left ventricular performance assessed by echocardiography. 1980

P A Chandraratna, and W S Aronow, and A Laddu

To assess the effects of acebutolol and propranolol on resting left ventricular function, 21 patients with coronary artery disease were studied. A baseline echocardiogram was obtained on day 1, and in a double-blind, randomized, crossover study the patients received 40 mg propranolo every 8 hr for 1 wk, 300 mg acebutolol every 8 hr for 1 wk, and 1 capsule placebo every 8 hr for 1 wk. On days 8, 15, and 22, after an echocardiogram at 7:30 A.M. (i.e., 7.5 hr after the midnight dose), they received double-blind randomized, crossover medications (acebutolol 300 mg, propranolol 40 mg, or placebo). The echocardiogram was repeated at 1.2, and 4 hr after placebo or propranolol and at 2, 3, and 5 hr after acebutolol. The left ventricular end diastolic dimension, left ventricular end systolic dimension, percent systolic shortening of the left ventricular minor axis, and ejection fraction were determined. We found that there was no significant difference between control values for any of the above parameters and those obtained at 1, 2, 4, or 7.5 hr after propranolol or placebo and at 2, 3, 5, or 7.5 hr after acebutolol. We conclude that in the doses used, acebutolol and propranolol do not induce depression of resting left ventricular function in patients with coronary artery disease who have normal or near normal left ventricular function at rest.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000070 Acebutolol A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action. Acebutolol Hydrochloride,Acetobutolol,Apo-Acebutolol,M & B 17803A,M&B-17803 A,Monitan,Neptal,Novo-Acebutolol,Prent,Rhotral,Sectral,Apo Acebutolol,ApoAcebutolol,M&B 17803 A,M&B17803 A,Novo Acebutolol,NovoAcebutolol

Related Publications

P A Chandraratna, and W S Aronow, and A Laddu
May 1985, American heart journal,
P A Chandraratna, and W S Aronow, and A Laddu
May 1984, Circulation,
P A Chandraratna, and W S Aronow, and A Laddu
October 1990, Clinical pharmacology and therapeutics,
P A Chandraratna, and W S Aronow, and A Laddu
June 1988, The American journal of cardiology,
P A Chandraratna, and W S Aronow, and A Laddu
July 1980, Clinical pharmacology and therapeutics,
P A Chandraratna, and W S Aronow, and A Laddu
August 1979, Clinical pharmacology and therapeutics,
P A Chandraratna, and W S Aronow, and A Laddu
January 1978, Medecine interne,
Copied contents to your clipboard!